CT-P51 + EU-approved Keytruda
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Squamous Non Small Cell Lung Cancer
Conditions
Non Squamous Non Small Cell Lung Cancer
Trial Timeline
Jan 30, 2025 → Jul 1, 2028
NCT ID
NCT06939595About CT-P51 + EU-approved Keytruda
CT-P51 + EU-approved Keytruda is a phase 3 stage product being developed by Celltrion for Non Squamous Non Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06939595. Target conditions include Non Squamous Non Small Cell Lung Cancer.
What happened to similar drugs?
4 of 20 similar drugs in Non Squamous Non Small Cell Lung Cancer were approved
Approved (4) Terminated (2) Active (14)
🔄Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06939595 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non Squamous Non Small Cell Lung Cancer